New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
08:08 EDTACTActavis shares should be bought, says Bernstein
Bernstein expects Actavis' cash generation to exceed the industry average by a significant amount. The firm raised its price target on the shares to $250 from $225 and keeps an Outperform rating on the stock.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:39 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
09:18 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
October 27, 2014
15:18 EDTACTEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
10:36 EDTACTAllergan delivers earnings beat, says willing to consider higher Valeant bid
Subscribe for More Information
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
October 22, 2014
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
October 21, 2014
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
06:28 EDTACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use